SCC80TH ANNUAL SCIENTIFIC MEETING & SHOWCASE
DECEMBER 1 - 2, 2026 | JW MARRIOTT LA LIVE LOS ANGELES, CA



CeraBloom®: Microbiome Metabolic Reprogramming for a New Generation of Barrier Care

Sollice Biotech

www.sollicebiotech.com

PRODUCT/SERVICE BACKGROUND INFORMATION

Ceramides are the main lipidic component of the skin barrier. Conventional ceramide ingredients either deliver lipids to the skin surface or stimulate the skin's own synthesis. Yet skin bacteria carry their own ceramide pathway (Spt, bCerS, CerR), long overlooked because annotation tools based on human enzymes were missing it.

CeraBloom® was designed by a computational platform that reads metabolic functions shared across skin microbiomes. First of its kind, it brings the concept of precision prebiotic made of specific shingolipids associated with palmitic acid for a targeted and measurable effect.

WHAT IS THE COMPANY INTRODUCING TO THE MARKET/INDUSTRY?

Together with its partner Cybele Microbiome, Sollice Biotech introduces **CeraBloom®**, a third route for ceramide care: it supplies the "building block" of the bacterial pathway so that the skin microbiome produces ceramides on site, as a natural "bio-factory".

In skin microbiome cultures, **CeraBloom®** generated a diverse ceramide spectrum measured by LC-MS-MS, including species neither precursor carries, while an intact ceramide was mainly hydrolyzed into free sphingosine. *In vitro*, it also protected skin bacteria against the potential adverse effect of some commercial ceramides and reduced microbiome-induced IL-8, IL-18 and TNF-α release by keratinocytes.

HOW WILL THIS NEW PRODUCT/SERVICE IMPACT THE INDUSTRY (BENEFITS)?

Sensitive, dry skin often hides a weakened barrier and an unbalanced microbiome, where ceramides are broken down faster than they are made. **CeraBloom®** acts upstream: it helps the skin's own bacteria rebuild their ceramides. In a placebo-controlled study, it kept ceramide breakdown in check, supported barrier function and hydration, reduced oiliness and visible pores, and favored S. epidermidis. In an open-label study, volunteers with sensitive skin reported 45% less sensitivity with 95% of volunteers reporting an improvement in sensitivity. CeraBloom® opens a new route for reactive and atopic-prone skin care while bringing in-situ beauty benefits to consumers.